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Available online 18 March 2016Background: hyperlipidemia is one of the most important cardiovascular risk factors. Statins at high doses are
commonly prescribed to lower LDL-cholesterol, but are often poorly tolerated. In particular, muscle pain and
increase of creatine phosphokinase are frequent side effects. The purpose of this study was to assess whether the
addition of a nutraceutical to simvastatin may result in the achievement of the therapeutic target (LDL-cholesterol
less than 70 mg/dL) without side effects in patients with ischemic heart disease.
Methods: Sixty-four patients with ischemic heart disease treated with simvastatin 20mgwho had not achieved the
therapeutic targetwere enrolled. Patientswere randomised 1:1. Patients of group A (n=32)were given simvastat-
in 40 mg per day and patients of group B (n = 32) were given simvastatin 20 mg plus 2 tablets of a nutraceutical
composed of bergamot, phytosterols, artichoke, vitamin C.
Results: After 3 months, patients in both groups showed a signiﬁcant reduction from baseline in total cholesterol,
LDL-c and tryglicerides. However, in group A, 4 patients reported myalgia (9,7%) with an increase in creatine
phosphokinase; whereas no adverse events occurred in group B.
Conclusions: The association of a nutraceutical and simvastatin 20 mg may be a valid therapeutic option for the
treatment of hyperlipidemia in patientswith ischemic heart disease intolerant to statin at high doses, in the absence
of side effects. Further studies are needed to clarify the mechanisms of action of nutraceuticals.
© 2016 Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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side effects1. Introduction
Hyperlipidemia is one of the most important cardiovascular risk
factors, associated to the development of several diseases such as
atherosclerosis [1], coronary heart disease (CHD) [2], cerebrovascular
ischemia and peripheral vascular disease [3].
Although the incidence of events related to cardiovascular disease is
declining in the western world [4], the latter is still the major cause of
morbidity and mortality of adults of average age and advanced age [5].
Further, the incidence and absolute number of events per year will
probably tend to increase in the next decade because of the rise in
obesity and the population aging [6,7].e reliability and freedom from
ion.
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).
is an open access article under the CRelatedly, increased blood concentrations of total cholesterol, low
density lipoprotein cholesterol (LDL-c) and triglycerides, often accom-
panied by low levels of high density lipoprotein-cholesterol (HDL-c)
comprise the main pathogenic risk proﬁle. Also, genetic abnormalities
and lifestyle (physical inactivity, diets high in calories, fatty acids and
cholesterol) contribute to the development of dyslipidemia, frequent
in developed countries [8,9]. Therefore, it is well known that treating
hypercholesterolemia reduces cardiovascular mortality and morbidity.
To date, EAS/ESC [10] and ACC/AHA [11] guidelines identify statin
drugs as the mainstay of therapy for hypercholesterolemia and for the
prevention of cardiovascular risk. For these reasons, the majority of
therapeutic protocols rely on these drugs.
Statins are competitive inhibitors of 3-hydroxy-3-methyl-glutaryl-
CoA (HMG-CoA) reductase, which catalyses an early and rate-limiting
step in cholesterol biosynthesis [12,13].
Statins are able to lower the levels of LDL-c from 20% to 55% depend-
ing on the dosage and the statin used [14]. Although statins exert clearly
theirmain effects on CHD by lowering the levels of LDL-c and improvingC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Characteristics at baseline of each treatment group.
GROUP A (n=32)
Simvastatin 40 mg
GROUP B (n=32)
Simvastatin 20 mg +
p
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been attributed to these drugs, such as the improvement of endothelial
function, the action on plaque stability and inﬂammation, reducing
levels of C-reactive protein and decreasing the risk of CHD [15,16].
Moreover, a decrease of 43% of thromboembolic events in patients
treated with a statin has been observed [17].
Among drugs currently marketed, statins are the most effective and
better tolerated agents for the treatment of dyslipidemia [18,19]. The
latest EAS/ESC guidelines indicate that in patients with ischemic heart
disease the therapeutic target for the levels of LDL-c is less than
70 mg/dL. This goal is reached only in patients who were prescribed
statins at high doses.
However, it is well known in clinical practice that taking statins at
high doses is often poorly tolerated for the occurrence of side effects
such asmuscle pain and increase of creatine phosphokinase (CPK) [20].
Moreover, despite the signiﬁcant clinical beneﬁts provided by statin
therapy, many patients do not achieve their recommended levels of
LDL-c and HDL-c with statins alone [21].
The onset of side effects and the importance of achieving the thera-
peutic target in patients at risk of cardiovascular events suggest the
need to ﬁnd alternative therapeutic approaches.
Experimental and epidemiological evidence suggests that dietary
polyphenols, in particular ﬂavonoids, may play a role in ameliorating ath-
erosclerosis, due to a pleiotropic anti-oxidative and anti-inﬂammatory
effect proposed as underlying mechanism [22].
In particular, Bergamot (Citrus bergamia Risso et Poiteau), an endem-
ic plant growing in the Calabrian region of Southern Italy, has a unique
proﬁle and a high content of ﬂavonoids and glycosides in its juice and
albedo such as neoeriocitrin, neohesperidin, naringin, rutin, neodesmin,
rhoifolin, poncirin [23,24].
Moreover, bergamot juice has been found to be rich in 3-hydroxy-3-
methylglutaryl neohesperidosides of hesperetin (brutieridin) and
naringenin (melitidin) [25] which demonstrated their activity on
inhibiting HMG-CoA reductase, both in animal models of diet-induced
hyperlipidemia [26], and in patients suffering from hyperlipidemia,
hyperglicemia and metabolic syndrome [27] showing a clear effect on
total-cholesterol, LDL-c, HDL-c, tryglicerides and glucose blood levels.
Recently, the activity of bergamot juiceﬂavonoids has been evaluated
in comparison to a statin in patients with metabolic syndrome, showing
that the addition of bergamot poliphenolic fraction (BPF) to rosuvastatin
signiﬁcantly enhanced rosuvastatin-induced effect on serum lipemic
proﬁle compared to rosuvastatin alone [28].
Taking into account all these issues, we conducted a randomised,
controlled, open-label study on patients suffering from ischemic heart
disease who had not achieved the therapeutic target with a previous
treatment with simvastatin 20 mg/day in order to evaluate the efﬁcacy
of the combination therapy of a statin and a nutraceutical. Speciﬁcally,
the purpose of the study was to assess whether the combination of a
nutraceutical (bergamot, phytosterols, artichoke and vitamin C) to
simvastatinmay result in the achievement of the target range in the ab-
sence of side effects. The primary endpointwas to verify the therapeutic
efﬁcacy of the combination of simvastatin and the nutraceutical, the
secondary endpoint was to evaluate their tolerability.Bergamot 400 mg
Age 62±15 64±12 ns
M/F 18/14 19/13 ns
BMI 26,4+±2,2 26,1+±2,3 ns
Smoke 11 10 ns
Hypertension 24 22 ns
Diabetes 3 4 ns
Beta blockers 30 31 ns
ACE inhibitors 26 25 ns
ARBs 5 5 ns
Ca antagonists 2 1 ns
Diuretics 1 1 ns
Antiplatelet 32 32 ns
ACE = angiotensin-converting-enzyme; ARBs = angiotensin receptor blockers; BMI =
body mass index; Ca = calcium; F = female; M=male; ns = non signiﬁcant.2. Methods
Sixty-four patients with ischemic heart disease who had not
achieved the therapeutic target, under treatment with simvastatin
20 mg, were enrolled.
An informed consent was obtained from each patient according to
the European Legislation and the protocol of the study was previously
submitted and approved by the Regional Ethical Committee.
In addition, the study protocol was performed according to the eth-
ical guidelines of the 1975Declaration of Helsinki, as reﬂected an a priori
approval by the institution's human research committee.Patients were randomised 1:1; patients of group A were given sim-
vastatin 40 mg while patients of group B continued their treatment
with simvastatin 20mg adding 2 tablets per day of a nutraceutical com-
posed (per each tablet) of 200mg of bergamot juice dry extract, 120mg
of phytosterols, 80 mg of artichoke leaf extract, 20 mg of vitamin C.
At enrollment and after 3 months patients underwent a clinical ex-
amination and blood tests to measure total cholesterol levels, HDL-c,
LDL-c, triglycerides, creatinine, glycemia, glutamic oxaloacetic transam-
inase (GOT), glutamic pyruvic transaminase (GPT), CPK.
A t-test for paired data was used to compare baseline and post-
treatment values for each group.
A chi square testwas performed to compare adverse events between
groups.
3. Results
Clinical and demographic characteristics between groups are reported
in Table 1.
After treatment, patients in group A showed a signiﬁcant reduction
from baseline in total cholesterol, LDL-c and tryglicerides, with a trend
towards signiﬁcance for increase in HDL-c (Table 2). Patients in group
B also showed a signiﬁcant reduction from baseline in total cholesterol,
LDL-c and tryglicerides, with a signiﬁcant increase in HDL-c.
In group A, 4 patients reported myalgia (9,7%) with an increase in
CPK, whereas no adverse events occurred in group B (p b 0.001). The
two groups did not differ for safety parameters, as shown in Table 3.
4. Discussion
The data presented in this study show that the association of the nu-
traceutical composed of bergamot, artichoke, phytosterols and vitamin
C to statin therapy, given orally for 3 months, allows the reduction of
daily dose of simvastatin while achieving target lipid values in patients
with ischemic heart disease.
In fact, patients taking the nutraceutical composed added to simva-
statin showed a reduction of both total cholesterol and LDL-c, of triglyc-
erides and an increase of HDL-c, without side effects.
Considering that side effects typical of statins are dose-dependent,
our aim was to demonstrate the efﬁcacy of an alternative therapeutical
approach for patients at high cardiovascular risk, without side effects.
This may also help improving patient compliance.
The results obtained in the group of the combination therapy are
comparable to those obtained with simvastatin at the highest dose
(40 mg), thus suggesting an additive effect of the nutraceutical with
lower doses of simvastatin.
In addition, the beneﬁcial effects of the combination therapy de-
scribed in this study were obtained in the absence of side effects typical
Table 2
Comparisons between baseline and post-treatment values within each treatment group.
GROUP A (n=32)
Simvastatin 40 mg
GROUP B (n=32)
Simvastatin 20 mg +Bergamot 400 mg
baseline 3-months p-value baseline 3-months p-value
Total cholesterol (mg/dl) 177+/-17 162+/-13 0.001 172+/- 21 151+/-16 b0.001
LDL-c (mg/dl) 107+/-9 92+/-5 b0.001 103+/-7 85+/-5 b0.001
HDL-c (mg/dl) 44+/-5 46+/-3 0.05 41+/- 4 43+/-3 0.023
Tryglicerides (mg/dl) 131+/-10 118+/-8 b0.001 139+/- 13 122+/-9 b0.001
HDL = high density lipoprotein; LDL = low density lipoprotein.
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a major cause of discontinuation of lipid-lowering therapy [29].
Nevertheless, beyond the clear anti-hyperlipidemic effect of the
nutraceutical, themechanism of action of the single substances remains
to be elucidated, as well as the possible synergistic effect of the natural
active ingredients within the formulation.
Several studies describe the cholesterol lowering effect of plant ste-
rols and plant stanols, by reducing intestinal absorption of exogenous
cholesterol [30].
Some studies have described the hypocholesterolaemic effect of ar-
tichoke leaf extract, a natural compound traditionally used for jaundice
and liver insufﬁciency [31]. Quantitative measurements show that
artichoke extract inhibits cholesterol biosynthesis in a concentration
dependent manner [32].
While some authors suggested cynarine (1.5-di-caffeoyl-D-quinic
acid) as the principal active component of artichoke [33], more recent
ﬁndings indicate a role for the ﬂavonoid luteolin in the inhibiting effects
of cholesterol synthesis [34].
With regard to the lipid-lowering effect of bergamot, several studies
described the properties of the ﬂavonoids, contained in high amount in
this species of the genus Citrus [35].
A major contribution to the hypolipidemic properties of bergamot
juice extract seems to be related to the modulatory properties in the ﬂa-
vanone glycoside component, in particular naringin and neo-hesperidin.
In addition to the antioxidant properties of the ﬂavonoids, the effect
of both naringin and hesperidin seems also to involve direct inhibition
of the HMG-CoA reductase enzyme system [36].
Furthermore, bergamot juice is rich in brutieridin andmelitidin, two
ﬂavanone derivatives which have been shown to selectively inhibit
HMG-CoA reductase [25].
Thus, their hypolipemic properties, mainly due to their content of
ﬂavonoids, may explain the above described beneﬁcial effect of the
compound of bergamot, artichoke and phytosterols in patients with
cardiovascular risk.5. Study limitations
Some limitations should be taken into account when interpreting our
results mentioned above. The main limitation of this study is its single-
blind design. In addition, the mechanisms of action of nutraceuticals
remain to be elucidated.Table 3
Safety parameters at baseline and after treatment within each treatment group.
GROUP A (n=32)
Simvastatin 40 mg
GROUP B (n=32)
Simvastatin 20 mg +
Bergamot 400 mg
baseline 3-months p baseline 3-months p
GOT 22±4 23±5 ns 21,5±4 23,5±4 ns
GPT 24±3 25±4 ns 25±3 25,5±4 ns
CPK 86±19 87±15 ns 89±13 87±20 ns
CPK= creatine phosphokinase; GPT= Glutamic Pyruvic Transaminase; GOT= Glutamic
Ossalacetate Transaminase.6. Conclusions
Our data show that the combination of a nutraceutical composed to
lower dose of simvastatin enhances the effect of the simvastatin alone in
normalising serum lipid proﬁle.
Clinically, this may allow a reduction in daily simvastatin doses for
reaching and maintaining patients to target levels of cholesterol.
This innovative approach could represent a useful tool in terms of
patient compliance to therapy, by reducing the occurrence of disorders
due to intolerance to statins. Further studies are needed to clarify the
mechanisms of action of nutraceuticals.
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